Abstract
Context: Asthma is multifaceted disease where many targets contribute towards its development and progression. Among these, adenosine receptor subtypes play a major role. Objective: MCD-KV-10, a novel thiazolo-thiophene was designed and evaluated pre-clinically for its implication in management of asthma. Materials and methods: This compound showed good affinity and selectivity towards A2A/A3 adenosine receptor (AR) subtypes. Furthermore, MCD-KV-10 was evaluated for in vitro lipoxygenase inhibition activity; in vivo mast cell stabilization potential and in vivo anti-asthmatic activity was done in ovalbumin-induced airway inflammation model in guinea pigs. Results: The compound showed good (>57%) inhibition of lipoxygenase enzyme and also effectively protected mast cell degranulation (>63%). The compound showed good anti-asthmatic activity as inferred from the in vivo studies. Discussion: These results indicate that MCD-KV-10 has an inhibitory effect on airway inflammation. Conclusion: Though, we have identified a potential candidate for management of asthma, further mechanistic studies are needed.
Author supplied keywords
Cite
CITATION STYLE
Patil, D., Dash, R. P., Thakur, S. K., Pandya, A. N., Venkatesh, P., Vasu, K. K., & Nivsarkar, M. (2015). Implication of novel thiazolo-thiophene derivative (MCD-KV-10) for management of asthma. Journal of Enzyme Inhibition and Medicinal Chemistry, 30(2), 229–239. https://doi.org/10.3109/14756366.2014.913035
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.